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The genetic regulation and physiological impact of
most lipid species are unexplored. Here, we profiled
129 plasma lipid species across 49 strains of the
BXD mouse genetic reference population fed either
chow or a high-fat diet. By integrating these data
with genomics and phenomics datasets, we eluci-
dated genes by environment (diet) interactions that
regulate systemic metabolism. We found quantita-
tive trait loci (QTLs) for94% of the lipids measured.
Several QTLs harbored genes associated with blood
lipid levels and abnormal lipid metabolism in hu-
man genome-wide association studies. Lipid species
from different classes provided signatures of meta-
bolic health, including seven plasma triglyceride spe-
cies that associated with either healthy or fatty liver.
This observation was further validated in an indepen-
dent mouse model of non-alcoholic fatty liver dis-
ease (NAFLD) and in plasma from NAFLD patients.
This work provides a resource to identify plausible
genes regulating the measured lipid species and
their association with metabolic traits.
INTRODUCTION
Lipids are central to all biological processes, from storing energy
to forming cell membranes to signaling (Han, 2016). Although
lipids are composed of few structural ‘‘building blocks,’’ their
vast combinatorial side chain possibilities yield 100,000
distinct endogenous molecular species (http://www.lipidmaps.
org) (Fahy et al., 2005). Understanding the physiological contri-
butions of these diverse lipids is important because species
within the same class have differential association with disease
states (Puri et al., 2009; Quehenberger and Dennis, 2011; RheeCell Systems 6, 1–1
This is an open access article under the CC BY-Net al., 2011). Moreover, routine measurements of whole-lipid
class abundance using enzymatic assays often do not correlate
with the abundance of individual lipid species in disease states
(Quehenberger and Dennis, 2011).
The endogenous lipid profile in mammals is determined by the
combined influences of genes, environmental factors, and their
interactions (GxE). The profile varies based on changes in dietary
lipids, de novo lipogenesis, and alterations in the activities of
the hundreds of enzymes that modulate length, desaturation,
and incorporationof fatty acids (FAs) intomore complex lipidmol-
ecules. Aberrant levels of storage lipids (triacylglycerol [TAG]),
circulating lipid-protein complexes (lipoprotein particles), and
membrane lipids (phospholipids [PL] and diacylglycerols [DAG])
have been linked to metabolic dysfunction, such as seen in the
metabolic syndrome, whose features include obesity, insulin
resistance, cardiovascular diseases, and non-alcoholic liver dis-
ease (NAFLD) (Farese et al., 2012; Han, 2016; Puri et al., 2009;
Quehenberger and Dennis, 2011). However, the contribution
of majority of the individual lipid species per se to metabolic
dysfunction or to a healthy metabolic state is poorly understood.
In the past decade, genome-wide association studies (GWAS)
have identified numerous genetic variants and loci associated
with different lipid classes and complex metabolic traits (Dewey
et al., 2016; Diabetes Genetics Initiative of Broad Institute of
Harvard and MIT, Lund University, and Novartis Institutes of
BioMedical Research et al., 2007; Willer et al., 2013); however,
these loci explain only 5%–20%of the variance observed (Johan-
sen et al., 2011; Manolio et al., 2009). This problem is furthermore
compounded as many traits, such as lipids, are strongly modu-
lated by GxE interactions, which are difficult to control in human
studies. In contrast, studies of mouse genetic reference popula-
tions (GRPs) in which environmental factors can be controlled
have been able to provide a stable platform for identifying major
genetic, environmental, and GxE factors influencing complex
traits (Hui et al., 2015; Sittig et al., 2016; Williams and Auwerx,
2015).While earliermousepopulation studieshave identified spe-
cific loci associated with different lipid classes (Hui et al., 2015;
Zhang et al., 2012), no study in a GRP has specifically profiled3, June 27, 2018 ª 2018 The Authors. Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nor has GxE been examined for these traits.
In this study,weperformed lipidomicprofilingacross49distinct
inbred strains of theBXDGRP (descending fromcrossesbetween
C57BL/6J mothers and DBA/2J fathers) fed either chow diet (CD)
or high-fat diet (HFD) and subjected, in parallel, to an extensive
battery of metabolic tests (Williams et al., 2016). Both genetic
andmultilayered omics approaches were used to gain a compre-
hensive understanding of the genetic and dietary impact on lipid
species and to uncover the potential of lipid species as signatures
of metabolic health.
RESULTS
Plasma Lipid Species Profile across the BXD GRP
To characterize the physiological significance of the plasma
lipids measured, we used 78 BXD cohorts from 49 different
strains—44 cohorts fed CD and 34 fed HFD (280 mice) for
21 weeks. While on their respective diet, mice underwent exten-
sive metabolic phenotyping (Williams et al., 2016; Wu et al.,
2014). Subsequently, mice were sacrificed in an overnight
fasted state and plasma samples were analyzed using a discov-
ery liquid chromatography-tandem mass spectrometry (LC-
MS/MS) lipidomics platform. Lipid species were separated via
reversed-phase chromatography and identified using high-
resolution precursor and fragmentation scans. Collectively, we
identified eight distinct lipid classes, including free fatty acids
(FFAs) (16 species), TAG (53 species), diacylglycerol (DAG)
(6 species), phosphatidylcholine (PC) (28 species), phosphati-
dylethanolamine (15 species), phosphatidylinositol (7 species),
phosphatidylglycerol (2 species), and coenzyme Q (2 species)
(Table S1). The high quality and reproducibility of the MS mea-
surements are demonstrated by the pairwise correlation of
technical and extraction replicates, showing consistent robust
correlation (Figure S1). Furthermore, we performed all possible
pairwise correlations between the lipid species from different
groups to assess the sensitivity of our measurements in detect-
ing global diet- and strain-driven differences (Figure 1A). The
correlation of all lipids within each strain (biological replicates)
in either diet (CD or HFD) was higher than within strain-across
diet (CD versus HFD) correlation, implying that the global effect
of diet is larger than that of the biological replicates of the
strains. As expected, the correlation across strains on a given
diet (either CD or HFD) was higher than across strain-across
diet correlation (Figure 1A). Hierarchical cluster analysis demon-
strated that most BXD cohorts segregated based on diet (Fig-
ure 1B), which was also evident in the first dimension (PC1) of
the principal-component analysis (PCA) (Figure 1C). However,
the variance explained by the sum of the first two principal
components is only 53%, which indicates that the lipidomic pro-
file of the BXDs is highly variable in both diets (Figure 1C). Of the
129 lipid species measured, 93 were significantly different
between the two dietary cohorts (53 upregulated and 40 down-
regulated, HFD versus CD) (Table S2), indicating a major effect
of diet on lipid profiles.
We next evaluated the impact of diet on monounsaturated
fatty acid (MUFA) and polyunsaturated fatty acid synthesis—
major determinants of the lipid profile—by analyzing the levels
of plasma FFAs (Figure 1D). Though the saturated fatty acids2 Cell Systems 6, 1–13, June 27, 2018and MUFAs were 13–19 times higher in the diet of HFD
versus CD cohorts, only stearic (18:0) and oleic (18:1n9) acids
were significantly increased in the plasma of HFD cohorts,
indicating their increased accumulation under HFD (Figure 1D,
top). Furthermore, the desaturation and elongation products of
18:1n9 (20:1n9, 22:1n9, 24:1n9) were not increased in HFD
cohorts. This indicates a specific accumulation/enrichment of
oleic acid side chains in lipid species increased on HFD (Figures
1D, top and 1E). Though the essential fatty acids (EFAs),
including linoleic (18:2n6) and linolenic (18:3n3) acids were
1.5 and 1.8 times higher in the diet of HFD cohorts, their levels
were decreased in the plasma of HFD cohorts (Figure 1D, bot-
tom). This may reflect increased utilization of the EFAs in HFD
cohorts to build long chain FFAs (e.g., 20:4n6 and 22:4n6) and
their use as an energy source, as demonstrated by increased
peroxisomal-b oxidation in HFD cohorts (Figure 1D, bottom).
To evaluate the effect of diet on side chain composition of lipid
species, we calculated the FA composition of all side chains from
the lipid species. (For co-eluting isobaric species [Table S1],
all possible FA combinations for which there was evidence
were used in this calculation.) The majority of side chains were
comprised of palmitic, stearic, oleic, palmitoleic, linoleic, arach-
idonic, and docosahexaenoic (DHA) acid (Figure 1E). Lipid spe-
cies with at least one palmitic, stearic, or oleic acid in their side
chain were enriched in HFD cohorts, while species with at least
one palmitoleic, linoleic, and linolenic acid in their side chain
were enriched in CD cohorts (Figure 1E). Lipid species with an
arachidonic acid side chain were either enriched in HFD or re-
mained unchanged, while lipids with DHA side chains were either
enriched in CD or remained unchanged (Figure 1E). Notably, the
dietary enrichment of all these FAs (except palmitic acid) in the
lipid species observed here also reflects the FFA profile seen
in Figure 1D. Taken together, these results demonstrate that
diet has a strong influence in determining the lipid profile, and
that FFAs in general can reflect the side chain enrichment of lipid
species. These data suggest that in HFD there may be a switch
toward lipid species being enriched in palmitic, stearic, and
oleic acids, while being depleted in linoleic acid, because of its
increased utilization, to meet the energy demand (metabolic
flexibility) since the energy from carbohydrate is only 27% kcal
in HFD versus 44% kcal in CD.
Plasma Lipid Species Have High Heritability
Next, we assessed the degree of genetic, dietary, and GxE regu-
lation of lipid species. Heritability (h2; percentage of trait variation
attributed to additive genetic factors) was calculated for all lipid
species within (CD and HFD) and across (CD + HFD/Mixed)
dietary groups (Belknap, 1998) (Figure 2A; Table S3). In addition,
the variation attributed by GxE, diet, and non-genetic, non-
dietary variance (Unexplained) was calculated (Figure 2A and
Table S3). Within a dietary cohort, more than half of the observed
variance in lipid levels could be explained by genetic differences
across strains (i.e., h2 R 50%) for the strong majority of lipid
species (80% in CD and 75% in HFD). Conversely, when dietary
cohorts were combined, only 22% of lipids had h2 above 50%
(Figure 2A, "Genetics (CD + HFD)"). However, even when the
dietary cohorts were combined, the diet-independent genetic
factor was the strongest contributor to variance explained (Fig-
ure 2A, Genetics versus [GxE, Diet and Unexplained effect]).
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Figure 1. Dietary Impact on the Plasma Lipids Measured
(A) Pairwise correlation to assess the sensitivity of MS to detect global diet- and strain-driven differences across 280 samples. Red dot representsmean; the three
lines represent median, upper, and lower quartile.
(B) Heatmap of unsupervised hierarchical clustering of 129 lipid species for each BXD cohort.
(C) PCA of all lipids in each BXD strain (indicated by the strain number).
(D) Schematic representation of the systemic profile of saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) (top) and polyunsaturated fatty
acids (PUFAs) (bottom) in BXDs, based on the levels of the free fatty acids (FFAs) measured. Significant changes (HFD versus CD; p < 0.05) for FFA levels, activity
of the desaturases and elongases (ratio of product and precursor FFA) are shown as red for increase or blue for decrease.
(E) Pie chart showing the dietary enrichment of eight common side chain FAs in the lipid species in either diet. Number in the center indicates the total number of
lipids having at least one indicated FA side chain. For each pie chart, the three colors represent the number of lipids (having the indicated FA side chain) increased
in HFD versus CD (red), CD versus HFD (blue), or unchanged (gray).
See also Figure S1, Tables S1 and S2.
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did not explain even 50% of observed variance for a single lipid
species. However, these three controlled factors—genetics,
environment, and GxE—explained more than half of the variance
for 85% of all lipid species, whereas only 15% lipids had more
than 50% of their variance attributed to unexplained factors (Fig-
ure 2A, ‘‘Unexplained’’). For many lipids, the variance in their
levels both within and across diets reflected their h2 and variance
explained by genetics (CD + HFD/Mixed), diet, and GxE (Table
S3). For instance, TAG(52:2) levels were significantly increased
by HFD, where the diet explained its maximal variance (48%)
(Figure 2B). Conversely, PC(20:1_22:6) levels were not different
between the two cohorts, showing high h2 in both diets and
mixed variance (attributed to genetic factors) explained most
of its variance (70%) and dietary effect was only 3% (Figure 2C).
Collectively, these results indicate a high degree of genetic regu-
lation of lipid species in both diets.Plasma Lipids Are Influenced by Many Genomic Loci,
Including Several Associated with Lipid Levels in
Human GWAS
Next, we mapped quantitative trait loci (QTL) for all lipid species
(lQTL), identifying 212 lQTLs in CD and 94 in HFD (Figure 3A
[lQTLs above blue dotted line] and Table S4). It is not surprising
that most lipids hadmore than one lQTL, given the fact that many
independent processes and pathways regulate lipid species.
Only three lipid species (DAG(36:2), TAG(54:1), and eicosenoic
acid/20:1) had the same lQTL position (within 5 Mb) in CD
and HFD (Figure 3A, black bold font), which signifies that diet
can influence the genetic factors regulating most lipid species.
Of note, the CD-HFD lQTL pair of DAG(36:2)—mixture of
[18:1_18:1 and 18:0_18:2]—mapped to the region containing
genes with protein coding variants involved in lipid metabolic
processes (Slc2a2, Kcnmb2, Bbs12, Fgf2, and Pld1), insulin
secretion and homeostasis (Slc2a2, Kcnmb2, and Bbs12)Cell Systems 6, 1–13, June 27, 2018 3
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Figure 2. Plasma Lipid Species Have High Heritability
(A) Heritability/variance explained of all lipid species. Number of lipids (out of
129) that haveR50%of their variance explained by the factors along the x axis
is indicated. Purple line represents median variance explained.
(B and C) Example of two lipid species having high h2 in both diets but highly
affected by diet (TAG(52:2)) (B), or unaffected by diet (PC(20:1_22:6)) (C). Bar
plot showing the variation of the two lipids in the BXD population is shown on
the left and the percentage of h2/variance explained by the different factors is
indicated in the graph as well as graphically represented on the right. Data are
represented as means ± SEM.
See also Table S3.
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tems (2018), https://doi.org/10.1016/j.cels.2018.05.009(Figure 3B, left). This finding is consistent with the role of DAGs in
insulin sensitivity (Farese et al., 2012) and the fact that DAG(18:0/
18:2) has been proposed as one of the 21 plasma lipid predictors
in the diabetes risk classification model (Wong et al., 2013).
Importantly, of these five lQTL genes, the glucose transporter
Slc2a2 (Dupuis et al., 2010)—associated with glucose levels,
type 2 diabetes, and metabolic syndrome—showed a strong
positive association with metabolic syndrome phenotypes along
with DAG(36:2) (Figure 3B, right). A prominent metabolic IQTL
hotspot, common to 14 lipid species, was observed on Chr2 in
CD (Figures 3A and 3C). This region (101–113 Mb) contained
10 genes (among others) encoding proteins involved in lipid
metabolic processes, including FoxO signaling, lipid transport,
and having phospholipase and acyl transferase activity (Fig-
ure 3C, bottom). Of note are Cat (catalase; FoxO signaling),
Pdhx (pyruvate dehydrogenase complex component X; acyl
transferase activity), Chrm5 (Cholinergic receptor, muscarinic 5;
phospholipase activity), and CD44 (CD44 antigen), which have
non-synonymous SNPs in the BXDs (Figure 3C, bottom). For4 Cell Systems 6, 1–13, June 27, 2018each lQTL, we have provided the lQTL genes having nsSNP/
ncSNP/indel in BXDs in Table S4. Of the 306 lQTLs, 172 lQTLs
harbor 97 genes (having non-synonymous SNPs in BXDs) that
are known to be directly associated with lipid metabolic
terms including ‘‘lipid metabolic process,’’ ‘‘lipid particle,’’ and
‘‘lipid binding,’’ transferase activity, transferring acyl groups’’
(Table S4).
Human GWAS have identified many genetic variants associ-
ated with plasma lipids and associated metabolic traits (http://
jjwanglab.org/gwasdb, https://www.ebi.ac.uk/gwas/) (Diabetes
Genetics Initiative of Broad Institute of Harvard and MIT, Lund
University, and Novartis Institutes of BioMedical Research
et al., 2007; Willer et al., 2013; Kathiresan et al., 2009). Because
of the close homology betweenmouse and human genomes, the
mouse can be used to add evidence to genes suggested by hu-
man studies. Taking advantage of these genes identified
in GWAS studies (Table S5), we screened the 306 lQTLs
(Table S4) for the presence of any human GWAS genes associ-
ated with plasma lipids and associated metabolic traits (Fig-
ure 3D). We applied a stringent approach by screening only
those lQTL genes that have non-synonymous SNPs in BXDs.
This screening identified 40 GWAS candidate genes (out of
494 GWAS genes) under 93 lQTLs: 65 lQTLs in CD from 55 lipids
and 28 lQTLs in HFD from 25 lipids (Figure 3D; Tables 1 and S5).
While 45 lipids in CD and 22 in HFD had only one lQTL harboring
the GWAS genes, 10 lipids in CD and 3 in HFD had 2 lQTLs each
harboring two different GWAS genes, indicating a polygenic
regulation of these lipid species by different genes (Figure 3D).
Only 12 lipids had lQTL in both diets, of which 10 mapped to
different GWAS loci in the two diets and only 2 (DAG(36:2)/
DAG(18:1_18:1 and 18:0_18:2), and eicosenoic acid_ 20:1)
mapped at the same GWAS loci (within 5 Mb) in both diets
(Figure 3A; Tables 1 and S5). Importantly, we found 6 syntenic
GWAS regions in humans (0.04–0.9 Mb) that were also syntenic
in mice (0.4–0.8 Mb) (Table 1 [genes indicated by prefix ‘‘#’’] and
S5 [genes indicated in red font]).
Apart from the genes in Table 1, some lQTLs harbored prom-
inent human GWAS genes (associated with blood lipids and
metabolic traits) that do not have non-synonymous SNPs in
BXDs but may be linked to the causal variant. For instance,
TAG(50:3) had a QTL at the locus of glucokinase regulatory pro-
tein (Gckr) and Lrpap1 (LDL receptor-related protein-associated
protein 1). Gckr is one of the most robust loci implicated in TAG
metabolism (Figure S2A) (Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund University, and Novartis Insti-
tutes of BioMedical Research et al., 2007). It has been replicated
in GWAS of plasma TAG concentration, NAFLD and hypertrigly-
ceridemia by an excess of rare variants in patients (Johansen
et al., 2011; Kathiresan et al., 2009; Speliotes et al., 2011).
Lrpap1 shares the same locus as Gckr (within 5 Mb) and has
been associated with TAG, HDL-C, and LDL-C (Figure S2A).
FA desaturase (Fads 1, 2, and 3) is another prominent gene,
which has been associated with TAG, PLs, and type 2 diabetes
in numerous GWAS studies (Diabetes Genetics Initiative of
Broad Institute of Harvard and MIT, Lund University, and Novar-
tis Institutes of BioMedical Research et al., 2007; Johansen et al.,
2011; Kathiresan et al., 2009; Speliotes et al., 2011) (Figure S2B).
In line, two TAGs and four PCs had lQTLs at the Fads locus
(Figure S2B). Interestingly the FADs locus is syntenic in both
A C
B
D
Figure 3. Plasma Lipids Are Influenced by Many Genomic Loci, Including Several Associated with Lipid Levels in Human GWAS
(A) Manhattan plot of lipid species. Lipids indicated in black bold font (DAG(36:3), TAG(54:1), and 20:1) have the same QTL position in CD and HFD. lQTLs with p
value < 0.01 are indicated on the plot. The black and blue dotted lines represent significant and suggestive QTL threshold, respectively.
(B) lQTLs for one of the three lipids (DAG(36:2)) having a QTL at the same locus in both diets (top-left). Select lQTL genes and their function are indicated below
(bottom-left). Pearson correlation of DAG(36:2) alongside the expression of its liver lQTL genes (in CD) with metabolic syndrome phenotypes (right).
(C) Hotspot region comprising 14 lQTLs on chromosome 2. Genes associated with lipid metabolism in this region are indicated below.
(D) Genes with protein coding variants under 306 lQTLs were screened for any known association with blood lipids and associated metabolic traits in human
GWAS. The screening identified 40 GWAS genes (with nsSNPs) from 93 lQTLs. 55/25 lipids contributed to 65/28 QTLs harboring GWAS genes in CD/HFD with
12 lipids in common across diet. 45/22 lipids mapped to one GWAS gene each in CD/HFD, whereas 10/3 lipids mapped to two different GWAS genes each.
See also Tables S4 and S5.
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tems (2018), https://doi.org/10.1016/j.cels.2018.05.009mice and humans (Figure S2B). These data suggest that a large
number of GWAS genes associated to total lipid levels in humans
can also regulate many individual lipid species.
Lipid Species Provide a Signature of Metabolic Health
Status
Since many lipid species shared common QTLs, we hypothe-
sized that they are correlated/co-regulated. To assess this, we
performed an unweighted correlation network analysis of all
the lipid species, giving an overview of interactions between
different lipid species and classes (Figures 4A and 4B). In both
CD and HFD cohorts, lipid species were highly correlated both
within and across different lipid classes. The network in both co-horts showed a strong dense grouping of TAGs, PCs, FFAs, and
DAGs (Figures 4A and 4B, red ellipse). This cluster is indicative of
the PC and TAG synthesis from DAG intermediates (Han, 2016).
Diet-specific interactions were also observed; e.g., TAGs with
high carbon number (56–64) were not connected in the CD
network but were integrated with other TAGs in the HFD network
(Figures 4A and 4B, green ellipse). These results suggest that
lipids across different classes are correlated, and that a change
in one or more species may impact the levels of many other lipid
species independent of the lipid class.
Based on this conception, we hypothesized that it may be
possible to predictmetabolic health based on the variation in lipid
levels and vice versa. From the extensive phenotypic profilingCell Systems 6, 1–13, June 27, 2018 5
Table 1. lQTLs Harboring Genes Associated with Abnormal Lipid Metabolism in Human GWAS
Lipid Diet Gene @ chr, Mb GWAS Phenotype GWAS Validated PMID
DAG(18:2_16:0) CD Insig2 @chr1, 121.30 TC, LDL-C 24097068
TAG [48:0, 50:0]
PC(32:2)
CD
HFD
Fmn2 @chr1, 174.50 TG 23063622
PC [(22:6_16:0), (19:0_22:6)]
PI(20:4_18:0)
CD
CD
Ifih1 @chr2, 62.59
#Grb14 @chr2, 64.91
#Cobll1 @chr2, 65.08
T1D
HDL-C, BMI
HDL-C, BMI
17554260
24097068, 25673412
24097068, 25673412
TAG [51:4, 52:4, 52:5, 54:7, (54:6)_2]
DAG(18:2_18:2), Oleic acid
PC [(36:1), (16:0_18:1), (18:0_20:5)]
CD
CD
CD
Cd44 @chr2, 102.81 TG, TC, HDL-C 23063622
Eicosenoic acid
PE [(18:1_18:2), (16:0_18:2)]
CD
CD
Plcb2 @chr2, 118.70
#Capn3 @chr2, 120.46
#Ubr1 @chr2, 120.86
TG
TG
TG
23063622
20686565, 24097068
25961943
TAG(58:9)
TAG(54:6)_2, PC(16:0_18:1)
CD
HFD
Plcg1 @chr2, 160.73
Cd40 @chr2, 165.05
TC
TG
27790247
23063622
DAG(36:2/18:1_18:1)
DAG(18:1_18:1)
CD
HFD
Slc2a2 @chr3, 28.69 fasting glucose 20081858
PC(36:2) CD Mttp @chr3, 138.089 TG 19060911
Nervonic acid CD Macf1 @chr4, 123.34 HDL-C 25961943
PC(18:0_16:0) CD Pigv @chr4, 133.66 TG, LDL-C, HDL-C 24097068, 28334899
TAG [(48:3), (50:3)]
Eicosenoic acid
CD
HFD
Nos3 @chr5, 24.36 TG, CAD 23063622, 26343387
TAG [53:2, 56:2, 51:1, 52:1, 54:1] CD Corin @chr5, 72.30 TG 23063622
PC [(17:1_18:2), (16:0e_20:4)] HFD Klhl8 @chr5, 103.86 TG, HDL-C 28334899
TAG [56:5, 53:3], PC(32:2) CD Alms1 @chr6, 85.58 TG, TC, HDL-C,
LDL-C
23063622
23063622
DAG(18:1_18:2)
PC(34:2), PE(20:0e_22:6)
TAG(50:3), PC [(16:0_18:1), (33:1)]
CD
CD
HFD
Apoe @chr7, 19.69 TC, HDL-C, LDL-C 25961943, 28371326
PC(20:0_22:6)
TAG(49:2), PI(18:0_18:2), PE(18:0_18:2)
CD
HFD
Ppp1r3b @chr8, 35.37 TC, HDL-C,
LDL-C, PL
25961943, 20686565,
21829377
TAG(58:4), PC(16:0_18:1) CD Msr1 @chr8, 39.58 TG 23063622
PC [(16:0e_20:4), (20:4_22:6), (38:2)]
PE(20:4_18:0)
CD
HFD
Pccb @chr9, 100.98
Acad11 @chr9, 104.06
TG, HDL-C
HDL-C, LDL-C
24097068, 25961943
28334899, 24097068
PC(32:2), PE [(16:0_18:1), (18:1_18:2)]
Nisinic acid
CD
CD
#Aloxe3 @chr11, 69.12
#Dlg4 @chr11, 70.017
Pld2 @chr11, 70.54
TG
TC, LDL-C
PL, TG
23063622
24097068
22359512, 25961943
TAG(54:2) HFD #Mpp3 @chr11, 101.99
#Cd300lg @chr11, 102.04
TG
HDL-C
24097068
28270201
FA [16:0, 20:4, 22:6, 18:0, 20:3]
TAG [(54:6)_1, 51:4, 50:4, 52:5, 48:3]
PC [(18:0_16:0), 20:4_18:0]
CD
CD
CD
Srp68 @chr11, 116.24 TG 23063622
PC(19:0_22:6) CD Sycp2l @chr13, 41.11 PL 21829377
Eicosenoic acid, DHA, PC(20:2_22:6)
Eicosenoic acid, DGLA, nisinic acid
TAG [48:1, 56:8], PC [(38:2), (20:4_22:6)]
CD
HFD
HFD
#Poc5 @chr13, 96.38
#Ankdd1b @chr13, 96.41
#Polk @chr13, 96.48
obesity
TG
TC, LDL-C
23563607
19060911
28270201, 28334899
PE [(20:2_22:6), (18:0e_18:1)]
PE [(18:0e_18:2), (20:0e_18:2)]
HFD
HFD
Map3k1 @chr13, 111.74 TG 28334899
TAG(52:3) CD Rmi2 @chr16, 10.83
Pdxdc1 @chr16, 13.83
HDL-C
TG
25961943
28334899
TAG [(56:8), (54:7)] HFD #Angptl4 @chr17, 33.77
#Btnl2 @chr17, 34.35
TG, HDL-C
lipid levels
25961943
19936222
PE(18:0e_22:6) CD Pnliprp2 @chr19, 58.75 PL 22359512
Each box (27 loci) of the table represents the lQTL(s) in either diet, harboring the indicated 40 human GWAS genes (having protein coding variants in
BXDs) and the GWAS phenotype associated with the gene(s). Genes indicated by the prefix # are syntenic in mice and humans (six loci). GWAS pheno-
type abbreviation: TG, triglyceride; TC, total cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; PL, phospholipid; BMI, body mass index;
T1D, type 1 diabetes; CAD, coronary artery disease. An extended version of this table is provided in Table S5. See also Figure S2 and Table S5.
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Figure 4. Association of Lipid Species with Metabolic Traits
(A and B) Spearman correlation network of all lipid species in CD (A) and HFD (B). Lipid species are color coded as 10 major lipid classes.
(C and D) Heatmap with an unsupervised hierarchical clustering of Spearman’s correlation rho value of 36 lipids with metabolic phenotypes. These 36 lipids show
the same correlation trend with metabolic phenotypes in both CD (C) and HFD (D). The horizontal green phenotype cluster represents healthy metabolic traits,
whereas the red cluster represents unhealthy metabolic traits. The vertical green lipid cluster represents the healthy markers of metabolic health/fitness, whereas
the red cluster represents the unhealthy markers of metabolic health/fitness. Table S6 provides the rho and p values for each lipid-phenotype correlation.
See also Figure S3 and Table S6.
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tems (2018), https://doi.org/10.1016/j.cels.2018.05.009performed in these mice (Williams et al., 2016), we acquired
30 unique traits reflective ofmetabolic health/fitness. These traits
included fat and lean mass, physical fitness (treadmill exercise,
activity wheel, VO2 max), oral glucose tolerance test, heart rate,
and plasma biochemical markers (e.g., alanine transaminase
[ALT], aspartate transaminase [AST], cholesterol, FFAs, etc.),
among others. Spearman correlation was calculated between
all lipid species and metabolic traits (Table S6). The correlation
rho value was used to perform a heatmap analysis with unsuper-
vised hierarchical clustering of all lipid species and metabolic
traits (Figure S3A). In both CD and HFD, two lateral clusters
(extreme right and left) of lipid species could easily be identified,
which correlated with most of the metabolic traits (Figure S3A).
From these two lateral clusters in each diet (Figure S3B), we iden-
tified 36 lipid species that showed the strongest correlations withmetabolic traits in both diets (Figures 4C and 4D). Among them,
19 lipids were identified as ‘‘healthy markers’’ in both diets (Fig-
ures 4C and 4D, vertical green cluster), since they positively
correlated with healthy metabolic traits (Figures 4C and 4D, hor-
izontal green cluster) and negatively with unhealthy traits (Figures
4C and 4D, horizontal red cluster). While 17 lipids were identified
as ‘‘unhealthy markers’’ showing the inverse correlation pattern
(Figures 4C and 4D, vertical red cluster). Note that FFA, kidney
weight, heart weight, and heart rate cluster with healthy meta-
bolic phenotypes. The fact that FFAs provide 60%–70% of the
heart’s energy requirement (van der Vusse et al., 2000), and are
also the predominant energy source for the kidney (tubular
epithelial cells) (Kang et al., 2015), explains the clustering of these
traits together. Interestingly, only 7 of the 36 lipids identified as
metabolic health predictors are among the most abundant lipidsCell Systems 6, 1–13, June 27, 2018 7
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Figure 5. Identification of Lipid Species as Markers of NAFLD
(A and B) Plasma and liver TAG concentration (A) and correlation (B) in BXD cohorts. Data are represented as means ± SEM.
(C and D) 55 common lipid species between plasma and liver were correlated using Spearman’s method. (C) Histogram of the rho correlation value of these
55 lipid pairs in CD (left) and HFD (right). (D) Correlation of rho values between CD and HFD from (C) to identify lipids, which behave similarly despite the dietary
switch. Green dots indicate lipid species with positive correlation (wherein dark green dots are significant; p < 0.05), red and orange dots indicate lipids with
negative correlation (wherein red dot is significant; p < 0.05). Purple dots indicate lipid species with opposite correlation in CD and HFD, reflective of GxE effect.
(E) Pearson correlation of nine significant lipid species identified in (D) (dark green and red dots) in liver and plasma.
(F) Correlation matrix showing the Pearson correlation of the nine lipids, alongside plasma and liver TAG with NAFLD readouts.
See also Figure S4 and Table S7.
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tems (2018), https://doi.org/10.1016/j.cels.2018.05.009in their class (PC(20:4_18:0), PC(20:4_16:0), PC(22:6_16:0),
PC(36:1), TAG(52:2), TAG(52:4), and TAG(54:3)); the remaining
29 lipids have relatively low abundance in plasma (Table S2).
Taken together, these data suggest that lipid species reflect
metabolic health and that the most abundant species may not
necessarily be the best predictors of health.
Identification of Signature Lipid Species for NAFLD
Since plasma lipids associated with metabolic traits, we next
tested this finding in the context of a disease. Taking advantage
of the liver lipid species measured from the same cohort of mice
from our companion article in this issue (Jha et al., 2018), we
tested whether plasma lipid species can be indicative of NAFLD,
characterized by excess TAG accumulation in liver (Kleiner et al.,
2005). Both in humans and different mouse strains, plasma and
liver TAG levels are highly variable and are not always increased
in NAFLD or by HFD, indicating a complex polygenic regulation8 Cell Systems 6, 1–13, June 27, 2018(Browning et al., 2004; Johansen et al., 2011; Kirk et al., 1995;
Lin et al., 2005; Romeo et al., 2008). In line, plasma and liver
TAG levels were highly variable in the BXDs, although no signif-
icant difference was observed between CD and HFD cohorts
(Figure 5A). Moreover, the liver and plasma total TAG levels did
not correlate (Figure 5B). Therefore, we sought to identify individ-
ual lipid species in plasma that are representative of their levels in
liver. Of the 55 common lipids measured in plasma and liver,
30 in CD and 21 in HFD correlated with a Spearman’s rho (abso-
lute value) > 0.32 (Figure 5C, orange and green bar; Table S7). In
addition, there was a strong positive correlation between the
common plasma and liver lipids across diets (Figure 5D). In
particular, plasma and liver values of nine of these lipids signifi-
cantly and tightly correlated across both diets (Figure 5D, dark
green and orange dots), implying that the plasma levels of these
lipids reflect their abundances in liver in both diets (Figure 5E). Of
these nine lipids, four TAG species (TAG: 52:2, 54:3, 56:3, and
Please cite this article in press as: Jha et al., Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes, Cell Sys-
tems (2018), https://doi.org/10.1016/j.cels.2018.05.00954:1) were increased in the HFD cohorts in both plasma and liver,
while three TAG species (52:5, 52:4, and 54:6) were increased in
the CD cohorts in both plasma and liver (Figures 5E and S4).
TAG(50:2) was significantly increased in HFD in plasma but not
in liver (Figure S4). DAG(L_P)/(DAG(18:2_16:0)) showed a nega-
tive correlation between liver and plasma (Figure 5E) because,
on HFD, it was decreased in plasma but increased in liver (Fig-
ure S4). The accumulation of DAG(L_P) in liver and reduction in
plasma (Figure S4) suggests that its release from liver into the
plasma may have been minimized.
Correlation analysis of these nine lipids, alongside total TAG
concentration in liver and plasma, was performed with pheno-
types linked with NAFLD, including fasting insulin, glucose,
cholesterol, ALT, AST, fat mass, liver mass, and body weight
(Figure 5F). For either diet, the total TAG concentration in plasma
or liver either did not correlate or had a weak correlation with
NAFLD-associated phenotypes, which was in contrast to the in-
dividual TAG species (Figure 5F). The TAGs: 52:2, 54:3, 56:3, and
50:2, showed positive correlation, while the TAGs: 52:5, 52:4,
and 54:6 showed negative correlation with the NAFLD readouts
in both diets in liver and plasma (Figure 5F, red and blue font,
respectively). Importantly, these seven lipids had high h2
(55%–84%) in plasma in both CD and HFD cohorts (Table S3).
Of note, DAG(L_P), which shows a negative correlation between
plasma and liver (increased in CD in plasma and in HFD in liver)
(Figures 5E and S4), is the only lipid among the nine lipids
showing an opposite correlation with NAFLD phenotypes
between liver and plasma (Figure 5F). TAG(54:1) can be consid-
ered a diet-specific NAFLD marker since it correlated positively
with NAFLD markers in CD and negatively in HFD, indicative of
a GxE effect, where the HFD effect reverses the genetic effect;
its h2 in CD being 57% and in HFD, 48% (Table S3). The unex-
plained variance for both TAG(54:1) and DAG(L_P) was 35%
and 48%, respectively (Table S3), suggesting that these two
lipids may be less reliable plasma signatures for NAFLD. These
findings suggest that elevation of TAGswith fewer double bonds:
52:2, 54:3, 56:3, and 50:2 comprises a pro-NAFLD signature,
whereas an increase in TAGs with more double bonds: 52:5,
52:4, and 54:6 comprises an anti-NAFLD signature, irrespective
of the diet. Notably, the pro-NAFLD TAGs: 52:2 and 54:3, and the
anti-NAFLD TAGs: 52:5, 52:4, and 54:6 are also among the sys-
temic unhealthy and healthy metabolic markers (Figures 4C and
4D). Our data also signify the importance of having a strong cor-
relation between a plasma and liver lipid in order for it to be es-
tablished as a disease signature.
Assessment of Identified NAFLD Signatures in Mice and
Humans
We then tested the relevance of these lipids as signatures
of fatty liver in a different mouse model of NAFLD (induced
by high-fat high-sucrose [HFHS] diet) and tested whether an
NAFLD lowering therapeutic intervention, i.e., nicotinamide
adenine dinucleotide (NAD+) precursor, nicotinamide riboside
(NR), impacts these lipid markers. As such, we compared the
liver lipids of mice fed CD or HFHS diet for 18 weeks, or mice
that were fed HFHS diet supplemented with NR 9 weeks after
the start of HFHS diet when they had already developed NAFLD
(a therapeutic intervention, HFHS + NR) (Figure S5A) (Gariani
et al., 2016). Though liver total TAG concentration was signifi-cantly elevated in the HFHS group and decreased by NR (Fig-
ure S5B) (Gariani et al., 2016), all individual TAG species did not
show this profile despite their uniform genetic background
(C57BL/6J) (Figure S5C). Of all the TAG species measured,
only 53% were increased in the HFHS cohort while 33% were
decreased and 14% remained unchanged (data not shown).
Importantly, all four pro-NAFLD lipids (TAGs: 52:2, 54:3, 56:3,
and 50:2) from the BXD HFD study (Figure 5F) were also
increased in C57BL6/J mice fed HFHS diet, whereas the three
anti-NAFLD lipids (TAGs: 52:5, 52:4, and 54:6) were decreased
in HFHS diet cohorts (Figure 6A). NR significantly lowered three
of the four pro-NAFLD lipids (TAGs: 54:3, 56:3, and 50:2), but
increased the anti-NAFLD lipids only to a slight extent (Fig-
ure 6A). Importantly, the pro-NAFLD lipids correlated positively,
whereas the anti-NAFLD lipids correlated negatively with
clinical NAFLD readouts (Figure 6B). Notably, the liver NAD+
levels correlated negatively with the pro-NAFLD lipids, and
positively with anti-NAFLD lipids (Figure 6B), fully in line with
our previous work, which showed that NAD+ levels are depleted
in steatotic livers and are replenished after NR treatment (Gar-
iani et al., 2016).
To further explore the clinical relevance of these findings, we
analyzed the plasma lipid species of healthy patients, patients
with steatosis, early-stage NASH (mild to moderate fibrosis
[F1 + F2]) and advanced-stage NASH (severe bridging fibrosis
or cirrhosis [F3 + F4]). The first dimension (PC1) of the PCA
of 55 TAG species segregated nearly all of the healthy individuals
from the steatosis and NASH group (Figure S5D). However, the
variance explained by the PC1 was only 46%, implying that
the TAG profile in humans is highly variable possibly due to
the high genetic variation (Figure S5D). Despite the significant
differences in total TAG plasma levels between the healthy and
NAFLD groups (Figure S5E), only a few individual TAG species
were significantly changed, which is in line with the findings
frommice. Only 20% of TAG species were increased in steatosis
versus healthy, while 64% increased in early-stage NASH versus
healthy and 49% increased in advanced-stage NASH versus
healthy group (data not shown). However, the pro-NAFLD
lipids were increased in steatosis and/or the two NASH groups.
Compared with the healthy group, TAG(50:2) was increased in
both steatosis and the two NASH groups (F1 + F2 and F3 +
F4), while TAG(52:2) was increased only in the twoNASH groups,
whereas TAG(54:3) and TAG(56:3) were increased in the two
NASH versus the steatosis groups (Figure 6C). Conversely, the
three anti-NAFLD lipids, TAG(52:5), TAG(52:4), and TAG(54:6),
were decreased in advanced-stage compared with early-stage
NASH (Figure 6C). In line, the pro-NAFLD lipids correlated
positively with NAFLD readouts, whereas the anti-NAFLD
markers correlated negatively (Figure 6D). Taken together, these
data confirm the findings from the BXDs in a different model of
diet-induced NAFLD in mice as well as in humans, indicating
that these lipid species may be a more universal signature of
NAFLD across different diets and also relevant in humans.
To obtain insight on the affinity of TAG-metabolizing enzymes
for the NAFLD signatures, we tested the association of adipose
triglyceride lipase—the rate limiting TAG-metabolizing enzyme—
with these NAFLD TAG signatures. Atgl expression in white adi-
pose tissue (WAT) negatively correlated with the pro-NAFLD sig-
natures and positively correlated with the anti-NAFLD signaturesCell Systems 6, 1–13, June 27, 2018 9
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Figure 6. Validation of NAFLD TAG Signatures in Mice and Humans
(A) Levels of pro- and anti-NAFLD signatures in livers of C57BL/6J mice fed on CD, high-fat high-sucrose-diet (HFHS) and HFHS diet supplemented with NR,
9 weeks after the initiation of HFHS diet (HFHS + NR). Data are represented as means ± SEM.
(B) Pearson correlation matrix of the pro- and anti-NAFLD signatures with NAFLD readouts including the NAS score (NAFLD activity score) and liver NAD+ levels.
(C) Levels of plasma NAFLD signatures in human subjects with various degrees of NAFLD. Data are represented as means ± SEM.
(D) Pearson correlation matrix of the NAFLD signatures with NAFLD readouts in human subjects.
(E) Pearson correlation ofAtgl expression in subcutaneousWATwith pro- and anti-NAFLD plasma TAG signatures in BXD strains. Formice: n = 6–9 per group. For
human subjects: n = 12, healthy; n = 7, steatosis; n = 14, early-stage NASH; n = 11, advanced-stage NASH. Differences in mean TAG species were compared
using two-sample t tests.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.
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tems (2018), https://doi.org/10.1016/j.cels.2018.05.009in both CD and HFD cohorts (Figure 6E). This correlation was also
observed with the expression of Atgl in other metabolic tissues
(liver, heart, and muscle) (Figure S5F); however, the strongest as-
sociation was observed with WAT Atgl expression, since Atgl
lipase activity is10 times higher inWAT comparedwith other tis-
sues (Haemmerle et al., 2006). These findings are consistent with
our previous experimental findings showing that Atgl is important
to provide protection from steatohepatitis and that Atgl-KO mice
aresusceptible todevelopNAFLD/NASH(Jhaetal., 2014). Inaddi-
tion, the pro-NAFLDsignatures in bothplasmaand liver correlated
positively with lipid biosynthetic pathways and negatively with
oxidative pathways (Figure S5G). Conversely the anti-NAFLD
signatures correlated positively with oxidative pathways and10 Cell Systems 6, 1–13, June 27, 2018negatively with lipid biosynthetic pathways (Figure S5G). Taken
together, these biological corroborations of the TAG signatures
provide proof of concept validation of the lipid species measured
and validate the usefulness of the resource.
DISCUSSION
Here we used a systems approach—combining genetics, lipido-
mics, and phenomics—to examine the dietary and genetic
regulation of plasma lipids and their potential to reflect metabolic
health status. Our study reveals that most plasma lipids have
high heritability andmap to a QTL, several of which harbor genes
associated with abnormal lipid metabolism in human GWAS. As
Please cite this article in press as: Jha et al., Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes, Cell Sys-
tems (2018), https://doi.org/10.1016/j.cels.2018.05.009suchwe show that changes in specific plasma lipids can be used
as signatures of metabolic health status. We further validate the
potential of seven TAG species as plasma signatures of NAFLD
in mice and humans.
As expected, the change in diet from CD (6% calories from fat)
to HFD (60% calories from fat) had a significant impact on a large
proportion (70%) of the plasma lipid species measured. Due to
the unique genetic background of each of the strains, evenwithin
the same dietary cohort, most lipids were highly variable across
strains, an observation similar to that in humans (Shin et al.,
2014). Across all conditions, roughly 50% of variation could be
attributed to diet-independent genetic factors, with an additional
10% of variation being attributable to uniform diet-induced
changes, or a strain-dependent response to dietary differences.
Together, our study can explain more than half of the observed
variation in plasma lipid levels for 85% of the 129 measured lipid
species. For the variation attributable to genetic or GxE factors,
we identified about 300 novel lQTLs containing known and novel
putative regulators of lipid metabolism. Taking advantage of
the known human GWAS loci/genes associated with blood lipid
levels and associated traits, we uncovered, via a cross-species
examination, the association between 40 human GWAS genes
and 93 lQTLs including 6 syntenic regions common in mice
and humans. This link underscores the power of mouse GRPs
beyond finding novel loci/genes controlling levels of lipid species
to their potential to complement human genetic studies. The fact
that our data are derived from a genetically diverse mouse pop-
ulation, which mimics the genetic variation observed in humans,
increases its translational value and suggests that such popula-
tions provide a proper setting for additional mechanistic studies
related to lipid metabolism.
Network analysis showed that lipid species are correlated and
co-regulated, both within and across lipid classes. This reso-
nateswith the underlying fact that any change in a lipidmetabolic
pathway induced by an experimental or physiological inter-
vention will almost assuredly result in compensatory changes
in other pathways affecting discrete lipid pools (Farese et al.,
2012). Our findings furthermore demonstrate that within the
same lipid class, some lipid species are associated with healthy
metabolic traits and others with unhealthy metabolic traits,
providing testimony to the fact that all lipid species in a class
do not have the same physiological impact (Farese et al., 2012;
Quehenberger and Dennis, 2011; Rhee et al., 2011). We tested
this computational finding by comparing the lipid species of
plasma (this study) and liver (Jha et al., 2018) and identified
plasma lipids that are reflective of liver lipid accumulation in
NAFLD across diets and genetic background. Our results
demonstrate that pro-NAFLD TAG signatures have fewer double
bonds compared with the anti-NAFLD TAG signatures. These
findings are in line with a previous study in humans showing
that TAGs with lower carbon and double bond content were
associated with increased risk of diabetes (Rhee et al., 2011)
and therefore underscores the potential of mouse population
genetics for translational research. Indeed, we validated the
TAG signatures in another dietary model of NAFLD and in human
NAFLD subjects with consistent results.
Some technical limitations in this study need to be consid-
ered. First, our lipidomic platform did not provide a complete
coverage of the whole-plasma lipidome. Many lipid classes,including ceramides, lysophospholipids, cholesterol esters,
etc., were not part of our validated lipidomics method at the
time these measurements were made. However, our goal was
to measure a substantial subset of the plasma lipids across hun-
dreds of samples in the most accurate way, and by the simplest
method, from only 20 mL of plasma, in order to power QTL and
other systems analyses. Second, our measurements do not pro-
vide absolute quantification of lipid species. Since the major
thrust of this work is the identification of genetic loci regulating
lipid levels and the association of lipid species with metabolic
phenotypes, the lack of absolute lipid concentrations does not
undermine our findings. We acknowledge that more work is
required to extend our other genetic and phenotypic findings,
which is beyond the scope of this current article. This resource,
however, lays the foundation for future mechanistic insight into
the complex biology of lipids.
In conclusion, this study uncovers the potential of plasma
lipidomics combined with systems genetics approaches in a
mouse population to identify signatures of health and disease.
Identifying genes and genetic variants associated with plasma
lipid species will enrich our understanding of biochemical path-
ways, while at the same time facilitating the design of new ther-
apies for metabolic diseases. The wealth of information on novel
lQTLs and the phenotypic footprint of these lipid species provide
a robust resource to the scientific community for further in silico
data analysis. Our findings illustrate the need, importance, and
scope of studying individual lipid species and provide a platform
for further mechanistic studies of lipid species, as also demon-
strated in our companion article (Jha et al., 2018).
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Mice
B Human Subjects
d METHOD DETAILS
B Metabolic Phenotyping of BXD Cohorts
B Plasma Clinical Traits of BXD Cohorts
B Lipidomics Sample Preparation and Analysis
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Bioinformatic and Genetic Analyses
B QTL Candidate Gene Retrieval
B BXD lQTL and Human GWAS Gene Overlap
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and eight tables and can be
found with this article online at https://doi.org/10.1016/j.cels.2018.05.009.
ACKNOWLEDGMENTS
We thank Center of Phenogenomics (EPFL) for performing BXD phenotyping
and R.W. Williams for BXDs and GeneNetwork maintenance. J.A. is supported
by grants from the E´cole Polytechnique Fe´de´rale de Lausanne, the SwissCell Systems 6, 1–13, June 27, 2018 11
Please cite this article in press as: Jha et al., Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes, Cell Sys-
tems (2018), https://doi.org/10.1016/j.cels.2018.05.009National Science Foundation (31003A-140780), the AgingX program of the
Swiss Initiative for Systems Biology (51RTP0-151019), and the NIH
(R01AG043930). D.J.P. is supported by a grant from NIH (R01GM115591).
M.T.M. and E.G.W. were supported by NIH fellowships (T32GM007215
and F32GM119190, respectively). J.C. is supported by NIH grants
R35GM118110 and P41GM108538. M.T. is supported by grant F3008 from
the Austrian Science Foundation.
AUTHOR CONTRIBUTIONS
Conceptualization, P.J., D.P., and J.A.; MS Extractions,Methodology, andMea-
surement, M.T.M.; Formal Analysis, M.B.S. and P.J.; Investigation and Analysis,
P.J.andP.M.Q.;DataCuration,P.J.andE.G.W.;SupervisionandSampleCollec-
tion (NAFLD Clinical Study), M.T. and E.H.; Supervision (MS), J.J.C. and D.P.;
Standardization (MS), A.J. andA.U.; Validation (Biomarkers andQTLs), P.J.; Vali-
dation (GWAS), P.J. andR.G.; Validation (MouseNAFLD), K.G.;Writing –Original
Draft, P.J. and J.A.; Writing – Review & Editing, P.J., J.A., D.J.P., M.T.M., and
E.G.W.; Visualization, P.J., E.G.W., J.A., and D.P.; Project Administration and
Funding Acquisition; J.A. and D.P.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: February 27, 2018
Revised: April 24, 2018
Accepted: May 11, 2018
Published: June 13, 2018
REFERENCES
Belknap, J.K. (1998). Effect of within-strain sample size on QTL detection and
mapping using recombinant inbred mouse strains. Behav. Genet. 28, 29–38.
Broman, K.W., Wu, H., Sen, S., and Churchill, G.A. (2003). R/qtl: QTL mapping
in experimental crosses. Bioinformatics 19, 889–890.
Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D.,
Cohen, J.C., Grundy, S.M., and Hobbs, H.H. (2004). Prevalence of hepatic
steatosis in an urban population in the United States: impact of ethnicity.
Hepatology 40, 1387–1395.
Dewey, F.E., Murray, M.F., Overton, J.D., Habegger, L., Leader, J.B., Fetterolf,
S.N., O’Dushlaine, C., Van Hout, C.V., Staples, J., Gonzaga-Jauregui, C., et al.
(2016). Distribution and clinical impact of functional variants in 50,726 whole-
exome sequences from the DiscovEHR study. Science 354, https://doi.org/10.
1126/science.aaf6814.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT Lund
University and Novartis Institutes of BioMedical Research, Saxena, R.,
Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker, P.I., Chen, H., Roix, J.J.,
Kathiresan, S., Hirschhorn, J.N., et al. (2007). Genome-wide association anal-
ysis identifies loci for type 2 diabetes and triglyceride levels. Science 316,
1331–1336.
Dupuis, J., Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., Jackson,
A.U., Wheeler, E., Glazer, N.L., Bouatia-Naji, N., Gloyn, A.L., et al. (2010). New
genetic loci implicated in fasting glucose homeostasis and their impact on type
2 diabetes risk. Nat. Genet. 42, 105–116.
Fahy, E., Subramaniam, S., Brown, H.A., Glass, C.K., Merrill, A.H., Jr., Murphy,
R.C., Raetz, C.R., Russell, D.W., Seyama, Y., Shaw, W., et al. (2005).
A comprehensive classification system for lipids. J. Lipid Res. 46, 839–861.
Farese, R.V., Jr., Zechner, R., Newgard, C.B., and Walther, T.C. (2012). The
problem of establishing relationships between hepatic steatosis and hepatic
insulin resistance. Cell Metab. 15, 570–573.
Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R.,
Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. (2016). Eliciting the mito-
chondrial unfolded protein response by nicotinamide adenine dinucleotide
repletion reverses fatty liver disease in mice. Hepatology 63, 1190–1204.
Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C.,
Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., et al. (2006).12 Cell Systems 6, 1–13, June 27, 2018Defective lipolysis and altered energy metabolism in mice lacking adipose tri-
glyceride lipase. Science 312, 734–737.
Han, X. (2016). Lipidomics for studying metabolism. Nat. Rev. Endocrinol. 12,
668–679.
Hui, S.T., Parks, B.W., Org, E., Norheim, F., Che, N., Pan, C., Castellani, L.W.,
Charugundla, S., Dirks, D.L., Psychogios, N., et al. (2015). The genetic archi-
tecture of NAFLD among inbred strains of mice. Elife 4, e05607.
Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S.K.,
Lass, A., Zimmermann, R., Zechner, R., Hoefler, G., et al. (2014). Role of adi-
pose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in
mouse models of steatohepatitis and endotoxemia. Hepatology 59, 858–869.
Jha, P., McDevitt, M.T., Gupta, R., Quiros, P.M., Williams, E.G., Gariani, K.,
Sleiman, M.B., Diserens, L., Jochem, A., Ulbrich, A., et al. (2018). Systems
Analyses Reveal Psychological Roles and Genetic Regulators of Liver Lipid
Species. Cell Syst. 6. Published online June 27, 2018. https://doi.org/10.
1016/j.cels.2018.05.016.
Johansen, C.T., Kathiresan, S., and Hegele, R.A. (2011). Genetic determinants
of plasma triglycerides. J. Lipid Res. 52, 189–206.
Kang, H.M., Ahn, S.H., Choi, P., Ko, Y.A., Han, S.H., Chinga, F., Park, A.S.,
Tao, J., Sharma, K., Pullman, J., et al. (2015). Defective fatty acid oxidation
in renal tubular epithelial cells has a key role in kidney fibrosis development.
Nat. Med. 21, 37–46.
Kathiresan, S., Willer, C.J., Peloso, G.M., Demissie, S., Musunuru, K., Schadt,
E.E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009). Common variants
at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56–65.
Kirk, E.A., Moe, G.L., Caldwell, M.T., Lernmark, J.A., Wilson, D.L., and
LeBoeuf, R.C. (1995). Hyper- and hypo-responsiveness to dietary fat and
cholesterol among inbred mice: searching for level and variability genes.
J. Lipid Res. 36, 1522–1532.
Kleiner, D.E., Brunt, E.M., VanNatta,M., Behling, C., Contos,M.J., Cummings,
O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., et al. (2005).
Design and validation of a histological scoring system for nonalcoholic fatty
liver disease. Hepatology 41, 1313–1321.
Li, M.J., Liu, Z., Wang, P., Wong, M.P., Nelson, M.R., Kocher, J.P., Yeager, M.,
Sham, P.C., Chanock, S.J., Xia, Z., et al. (2016). GWASdb v2: an update
database for human genetic variants identified by genome-wide association
studies. Nucleic Acids Res. 44, D869–D876.
Lin, X., Yue, P., Chen, Z., and Schonfeld, G. (2005). Hepatic triglyceride
contents are genetically determined in mice: results of a strain survey. Am.
J. Physiol. Gastrointest. Liver Physiol. 288, G1179–G1189.
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H.,
McMahon, A., Milano, A., Morales, J., et al. (2017). The new NHGRI-EBI
Catalog of published genome-wide association studies (GWAS Catalog).
Nucleic Acids Res. 45, D896–D901.
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter,
D.J., McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al.
(2009). Finding the missing heritability of complex diseases. Nature 461,
747–753.
Puri, P., Wiest, M.M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H.K.,
Contos, M.J., Sterling, R.K., Fuchs, M., Zhou, H., et al. (2009). The plasma lip-
idomic signature of nonalcoholic steatohepatitis. Hepatology 50, 1827–1838.
Quehenberger, O., and Dennis, E.A. (2011). The human plasma lipidome.
N. Engl. J. Med. 365, 1812–1823.
Rhee, E.P., Cheng, S., Larson, M.G., Walford, G.A., Lewis, G.D., McCabe, E.,
Yang, E., Farrell, L., Fox, C.S., O’Donnell, C.J., et al. (2011). Lipid profiling iden-
tifies a triacylglycerol signature of insulin resistance and improves diabetes
prediction in humans. J. Clin. Invest. 121, 1402–1411.
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A.,
Boerwinkle, E., Cohen, J.C., and Hobbs, H.H. (2008). Genetic variation
in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat.
Genet. 40, 1461–1465.
Shin, S.Y., Fauman, E.B., Petersen, A.K., Krumsiek, J., Santos, R., Huang, J.,
Arnold, M., Erte, I., Forgetta, V., Yang, T.P., et al. (2014). An atlas of genetic
influences on human blood metabolites. Nat. Genet. 46, 543–550.
Please cite this article in press as: Jha et al., Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes, Cell Sys-
tems (2018), https://doi.org/10.1016/j.cels.2018.05.009Sittig, L.J., Carbonetto, P., Engel, K.A., Krauss, K.S., Barrios-Camacho, C.M.,
and Palmer, A.A. (2016). Genetic background limits generalizability of geno-
type-phenotype relationships. Neuron 91, 1253–1259.
Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., Hernaez, R., Kim, L.J.,
Palmer, C.D., Gudnason, V., Eiriksdottir, G., Garcia, M.E., Launer, L.J., et al.
(2011). Genome-wide association analysis identifies variants associated with
nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
PLoS Genet. 7, e1001324.
Stefely, J.A., Kwiecien, N.W., Freiberger, E.C., Richards, A.L., Jochem, A.,
Rush, M.J.P., Ulbrich, A., Robinson, K.P., Hutchins, P.D., Veling, M.T., et al.
(2016). Mitochondrial protein functions elucidated by multi-omic mass spec-
trometry profiling. Nat. Biotechnol. 34, 1191–1197.
van der Vusse, G.J., van Bilsen, M., and Glatz, J.F. (2000). Cardiac fatty acid
uptake and transport in health and disease. Cardiovasc. Res. 45, 279–293.
Wang, X., Pandey, A.K., Mulligan, M.K., Williams, E.G., Mozhui, K., Li, Z.,
Jovaisaite, V., Quarles, L.D., Xiao, Z., Huang, J., et al. (2016). Joint mouse-hu-
man phenome-wide association to test gene function and disease risk. Nat.
Commun. 7, 10464.
Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S.,
Kanoni, S., Ganna, A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013).Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45,
1274–1283.
Williams, E.G., and Auwerx, J. (2015). The convergence of systems and reduc-
tionist approaches in complex trait analysis. Cell 162, 23–32.
Williams, E.G., Wu, Y.B., Jha, P., Dubuis, S., Blattmann, P., Argmann, C.A.,
Houten, S.M., Amariuta, T., Wolski, W., Zamboni, N., et al. (2016). Systems
proteomics of liver mitochondria function. Science 352, aad0189.
Wong, G., Barlow, C.K., Weir, J.M., Jowett, J.B., Magliano, D.J., Zimmet, P.,
Shaw, J., and Meikle, P.J. (2013). Inclusion of plasma lipid species improves
classification of individuals at risk of type 2 diabetes. PLoS One 8, e76577.
Wu, Y., Williams, E.G., Dubuis, S., Mottis, A., Jovaisaite, V., Houten, S.M.,
Argmann, C.A., Faridi, P., Wolski, W., Kutalik, Z., et al. (2014). Multilayered ge-
netic and omics dissection of mitochondrial activity in a mouse reference pop-
ulation. Cell 158, 1415–1430.
Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). clusterProfiler: an R package
for comparing biological themes among gene clusters. OMICS 16, 284–287.
Zhang, W., Korstanje, R., Thaisz, J., Staedtler, F., Harttman, N., Xu, L., Feng,
M., Yanas, L., Yang, H., Valdar, W., et al. (2012). Genome-wide association
mapping of quantitative traits in outbred mice. G3 (Bethesda) 2, 167–174.Cell Systems 6, 1–13, June 27, 2018 13
Please cite this article in press as: Jha et al., Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes, Cell Sys-
tems (2018), https://doi.org/10.1016/j.cels.2018.05.009STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
Q6 internal standard Avanti Polar Lipids Cat# 900150
PC(15:0/15:0) internal standard Avanti Polar Lipids Cat# 850350P
PS(17:0/17:0) internal standard Avanti Polar Lipids Cat# 840028P
PE(15:0/15:0) internal standard Avanti Polar Lipids Cat# 850704P
PA(17:0/17:0) internal standard Avanti Polar Lipids Cat# 830856P
PG(15:0/15:0) internal standard Avanti Polar Lipids Cat# 840446P
CL(56:0) internal standard Avanti Polar Lipids Cat# 750332P
FA(15:0/15:0) internal standard, Pentadecanoic Acid Sigma-Aldrich Cat# 91446
SPLASH Lipidomix Mass Spec Standard j 330707 Avanti Polar Lipids Cat# 330707
Critical Commercial Assays
AST: AST Flex reagent cartridge Siemens Healthcare Cat# DF41A
ALT: ALTI Flex reagent cartridge Siemens Healthcare Cat# DF143
LDL: ALDL Flex reagent cartridge Siemens Healthcare Cat# DF131
HDL: AHDL Flex reagent cartridge Siemens Healthcare Cat# DF48B
Cholesterol: CHOL Flex reagent cartridge Siemens Healthcare Cat# DF27
Plasma TG: TGL Flex reagent cartridge Siemens Healthcare Cat# DF69A
LDH: LDI Flex reagent cartridge Siemens Healthcare Cat# DF54
HR Series NEFA-HR(2) FUJIFILM Wako Dignostics http://www.wakodiagnostics.com/r_nefa.html
Glucose: GLUC Flex reagent cartridge Siemens Healthcare Cat# DF40
Mercodia Mouse Insulin ELISA kit Mercodia Cat# 10-1247-01
Liver TG: Serum Triglyceride Determination Kit Sigma-Aldrich Cat#TR0100
Deposited Data
BXD plasma lipidomics data [raw] This paper https://chorusproject.org/anonymous/download/
experiment/1b742397d9114a27bcd63b40db2057f2
BXD plasma lipidomics data [normalized] This paper http://www.genenetwork.org/
GN Accession: GN602. RecordIDs 19545-19802
BXD mouse genotype data http://www.genenetwork.org/ GN Accession: GN600
BXD mouse metabolic phenotype data http://www.genenetwork.org/ GN Accession: GN602
BXD mouse liver transcriptome data http://www.genenetwork.org/ GN Accession: GN432 (CD),
GN431 (HFD)
BXD mouse Subcutaneous WAT transcriptome data http://www.genenetwork.org/ GN Accession: GN779 (CD),
GN778 (HFD)
BXD mouse heart transcriptome data http://www.genenetwork.org/ GN Accession: GN485 (CD),
GN486 (HFD)
BXD mouse quadriceps transcriptome data http://www.genenetwork.org/ GN Accession: GN379 (CD),
GN380 (HFD)
GWASdb2 (Li et al., 2016) http://jjwanglab.org/gwasdb
GWAS Catalog (MacArthur et al., 2017) https://www.ebi.ac.uk/gwas/
Software and Algorithms
R The R Foundation https://www.r-project.org/
MATLAB Mathworks https://www.mathworks.com
MATLAB Bioinformatics Toolbox Mathworks https://www.mathworks.com/products/bioinfo.html
corrgram The R Foundation https://cran.r-project.org/web/packages/
corrgram/index.html
R/qtl (v 1.39-5) package (Broman et al., 2003) http://www.rqtl.org/
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Unweighted correlation network custom package imsbInfer Github (https://github.com/wolski/imsbInfer)
biomaRt Bioconductor http://bioconductor.org/packages/biomaRt/
clusterProfiler (Yu et al., 2012) https://bioconductor.org/packages/release/
bioc/html/clusterProfiler.html
LipidSearch Thermo Scientific https://www.thermofisher.com/order/catalog/
product/IQLAAEGABSFAPCMBFK
GraphPad Prism 7 GraphPad https://www.graphpad.com/
Other
Q Exactive mass spectrometer, Build 2.3 SP2 Thermo Scientific https://www.thermofisher.com/order/catalog/
product/IQLAAEGAAPFALGMAZR
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Johan
Auwerx (admin.auwerx@epfl.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
BXD strains were obtained from University of Tennessee Health Science Center (Memphis, TN, USA) and JAX (The Jackson Labo-
ratory) and bred at the E´cole Polytechnique Fe´de´rale de Lausanne (EPFL) animal facility for more than two generations before incor-
poration into the study. Cohorts of 49 BXD strains with5 males each on CD and HFDwere used in this study. Mice were fed a chow
diet [CD; 2018 Teklad Global 18% Protein Rodent Diet (6.2% kcal from fat; 44.2% kcal from carbohydrate; 18.6% kcal from protein)]
or a high fat diet [HFD; Harlan Teklad, TD.06414 (60.3% kcal from fat; 27.3% kcal from carbohydrate; 18.4% kcal from protein)] for
21 weeks, starting at 8 weeks of age. All mice were phenotyped as described (Williams et al., 2016) (see Method Details section). At
week 29, animals were fasted overnight before sacrifice at 9:00 am. Blood was collected from isoflurane anesthetized mice via the
vena cavae, and immediately afterwards the animals were perfused with ice cold PBS, through the left ventricle. Blood was collected
in lithium-heparin (LiHep)–coated tubes (Microvette CB 300 Hep-Lithium, Sarstedt) shaken and kept in ice. The blood samples were
centrifuged at 4500 revolutions per minute (rpm) for 10 min at 4C before being flash-frozen in liquid nitrogen. Due to insufficient
plasma from all cohorts, lipidomics analysis could be performed only on 44 CD and 34 HFD strains with 2-5 mice/strain.
For in vivo validation of the lipid markers in mice, lipidomics was performed on liver samples from our previous study (Gariani et al.,
2016). In brief, male C57BL/6Jmice were separated into three groups at the age of 7 weeks. Animal cohorts were fed a CD, aWestern
high-fat and high-sucrose (HFHS) diet [HFHS; Harlan Teklad, TD.08811, (44.6% kcal from fat; 40.7% kcal from carbohydrate; 14.7%
kcal from protein)] or a HFHS diet that was supplemented with NR (400 mg/kg/day) at week 16 till week 25 (9 weeks) (HFHS+NR).
Mice were sacrificed after a 4hr fast at 9:00 am. All mice experiments were approved by the Swiss cantonal veterinary authorities
of Vaud under licenses 2257, 2257.1 and 2465.
Fatty Acid Composition (%) in the Diet of BXD CohortsFatty Acids Symbol CD HFD
Palmitic C16:0 0.7 8.02
Stearic C18:0 0.2 3.93
Oleic C18:1n9 1.2 14.68
Linoleic C18:2n6 3.1 4.7
Linolenic C18:3n3 0.3 0.55
Saturated fat 0.9 12.48
Monounsaturated fat 1.3 16.05
Polyunsaturated fat 3.4 5.4
Total fat 6.2 34.3Cell Systems 6, 1–13.e1–e6, June 27, 2018 e2
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Human Study Design and Participants
The prospective cohort consisted of patients agedR 18 years with biopsy-proven NASH and healthy controls who agreed to partic-
ipate in the study. Prospective sample collection was approved by local Ethic committee of Medical University of Vienna number:
474/2011 (patient), 1022/2013 (controls) and all subjects were included after obtaining written inform consent. Subjects were
excluded if they had history of current and past alcohol consumption of more than 20-30 g per day, presence of other liver diseases,
secondary causes of NAFLD, medications known to cause fatty liver during the previous 6 months and inability to provide informed
consent. Demographic data of all participants (29 males, 15 females) were obtained by structured interview. Their clinical data is
provided below. Liver biopsies were evaluated by a board certified pathologist to score for histologic features, according to the
histologic scoring system (NAFLD Activity Score) developed by Kleiner et al., (Kleiner et al., 2005). Patients were classified
into 3 groups based on fibrosis score: simple steatosis (no fibrosis), early stage NASH (fibrosis stage 1-2), advanced stage NASH
(fibrosis stage 3-4).
Human Plasma Biochemistry
Fasting whole blood samples were obtained by venipuncture after an overnight fast of 8 hours or more and processed for plasma
within 2 hours on the day of liver biopsy. Routine blood tests were performed at the university hospital of Medical University of Vienna
and included measures of ALT, AST, fasting TAG, cholesterol, glucose and insulin. The clinical information of the participants is
provided in the table below.Healthy Steatosis NASH, Early Stage NASH, Adv. Stage p-value
Age (years) 27.83 ± 1.64 42.14 ± 3.29 46.43 ± 3.77 58.18 ± 2.78 a,b,c,e,f
Body weight 65.4 ± 1.92 105.14 ± 10.63 94.92 ± 4.79 111.64 ± 8.90 a,b,c
BMI (Kg/m2) 21.89 ± 0.50 33.91 ± 3.21 32.37 ± 1.63 36.95 ± 2.79 a,b,c
Fibroscan (kPa) 4.28 ± 0.28 9.03 ± 2.41 8.81 ± 1.21 19.58 ± 2.88 c,e,f
Steatosis (%) - 38.57 ± 7.46 64.64 ± 5.70 45.45 ± 8.08 d
NAS score - 3.29 ± 0.47 4.93 ± 0.29 4.64 ± 0.48 d
ALT (U/L) 18.92 ± 1.43 50.14 ± 6.97 84.79 ± 15.34 70 ± 10.98 b,c
AST (U/L) 22.50 ± 1.31 30.29 ± 2.73 44.79 ± 5.14 72.82 ± 27.52 c
Cholesterol (mg/dl) 173 ± 11.39 204.71 ± 25.37 179.21 ± 9.82 173.09 ± 9.76
Triglyceride (mg/dl) 73.25 ± 7.71 190.43 ± 36.18 167.14 ± 17.21 140.82 ± 2 a,b
Fasting glucose (mg/dl) 84.08 ± 2.30 100.14 ± 6.60 138.43 ± 15.81 120.18 ± 9.53 b
Fasting insulin (mU/mL) 6.70 ± 1.11 24.33 ± 10.06 19.34 ± 1.91 23.72 ± 3.16 a,c
Subjects: n=44; 12 healthy, 7 steatosis, 14 early stage NASH, 11 adv. Stage NASH
Values of mean ± SEM are represented.
*p<0.05 from one-way ANOVA with Tukey’s multiple comparison test correction.
Significant difference between groups are indicated as:
‘‘a’’ between Healthy and Steatosis
‘‘b’’ between Healthy and NASH, early stage
‘‘c’’ between Healthy and NASH, Adv. Stage
‘‘d’’ between Steatosis and NASH, early stage
‘‘e’’ between Steatosis and NASH, Adv. Stage
‘‘f’’ between NASH, early stage and NASH, Adv. stageMETHOD DETAILS
Metabolic Phenotyping of BXD Cohorts
Metabolic phenotyping including, OGTT, heart rate, exercise performance test (VO2 max. and activity wheels) and EchoMRI) were
performed as described (Williams et al., 2016) and elaborated below.
Oral Glucose Tolerance Test (OGTT)
At 17 weeks of age, after 9 weeks of dietary treatment, all cohorts underwent an oral glucose tolerance test. Mice were fasted
overnight before the test, and fasted glucose was tested with a glucometer at the tail vein. Mice were then weighed and given
an oral gavage of 20% glucose solution at 10 mL per kg of weight. Glucometer strips were used at 15, 30, 45, 60, 90, 120, 150,
and 180 min after the gavage to examine glucose response over time. Blood was also collected at 0 (pregavage), 15, and 30 min
to examine insulin levels.e3 Cell Systems 6, 1–13.e1–e6, June 27, 2018
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Two weeks later, at 19 weeks of age, a noninvasive heart rate measurement was performed using a tail-cuff system (BP-2000 Blood
Pressure Analysis System, Series II, Visitech Systems) over 4 days. The first 2 days were considered as adaptation to the apparatus,
and the second 2 days were used for data analysis, and heart rate measurements were averaged across both days. Outliers on a
per-measurement basis were removed, but outlier mice were retained.
Exercise Performance Test
At 23 weeks of age, all mice performed a VO2 max treadmill experiment (pre-training) using the Metabolic Modular Treadmill
(Columbus Instruments). For the first 15 min in the machine for each mouse, the treadmill was off while basal respiratory parameters
were calculated. The last 2minutes of data before the treadmill turned onwere considered basal levels (most mice spend the first few
minutes exploring the device). The treadmill then started at a pace of 4.8 m per minute (m/min), followed by a gradual increase
over 60 s to 9 m/min, then 4 min at that pace before increasing to 12 m/min over 60 s, then four min at that pace before increasing
to 15 m/min over 60 s, then 4 min at that pace, then the speed increased continuously by 0.015 m per second (or +0.9 m/min) there-
after until the end of the experiment at 63.5 min, 1354.5 m, or when the mouse is exhausted. CD cohorts ran against a 10 incline,
whereas HFD cohorts were set at 0. For this test, no mice reached the maximum distance recorded by the machine—all were taken
out when exhausted (considered as inability to run). The distance run, maximum VO2, and maximum RER were recorded. Maximum
VO2 and RER were taken by averaging the last ten measurements. Immediately after the treadmill experiment, mice were placed in
individual open-air cages with ad libitum access to activity running wheels (Bioseb BIO-ACTIVW-M, Vitrolles, France) for 10 days. For
most strains (with some exceptions), all 10 days of activity wheel usage was recorded, for others the average of last 24 hrs was taken.
This running distance constitutes the "24hr run distance" phenotype. After the 10th day, at 25 weeks of age, mice underwent an
identical VO2 max treadmill experiment (post-training) as described above at 23 weeks of age. After this experiment, mice were
returned to their standard housing cages—individually—for 4 weeks. Mice were fasted overnight before they were sacrificed.
Body Composition (EchoMRI)
In addition to the body weight measurements taken each week and before each phenotyping experiment, body composition was
recorded at 16, 23, and 25 weeks of age. To do so, each mouse was placed briefly in an EchoMRI (magnetic resonance imaging)
machine (the 3-in-1, EchoMedical Systems), where lean and fat mass are recorded, along with total body weight, taking 1 min
per individual.
All tests were normalized to total body weight in our analyses.
TAG Measurement of BXD Livers
For BXDs, 15ml of the liver lipid extract (same extract as used for liver lipid MSmeasurement, see companion article [Jha et al., 2018])
was used for TAG quantification using the Serum Triglyceride determination kit (Sigma-Aldrich), as per manufacturer’s instructions.
The organic solvent mix used for dissolving lipids for the MS (mixture of acetonitrile (ACN)/isopropyl alcohol (IPA)/water (H2O),
(65:30:5, v/v/v, 100mL)) was used as blank and for standard curve.
NAD+ Measurement of C57BL/6J Livers
20mg of frozen liver samples were used for NAD+ extraction in 10%perchloric acid and neutralized in 3MK2CO3 on ice. After centri-
fugation, the supernatant was filtered and the internal standard (NAD-C13) was added and loaded onto a column (150 A˚ 2.1 mm;
Kinetex EVOC18, 100 A˚). HPLCwas run for 1 min at a flow rate of 300ml/min with 100% buffer A (Methanol/H2O, 80/20% v,v). Then,
a linear gradient to 100%buffer B [H2O+ 5mMammonium acetate] was performed (at 1 to 6min). Buffer B (100%)wasmaintained for
3 min (at 6 to 9 min), and then a linear gradient back to 100% buffer A (at 9 to 13 min) began. Buffer A was then maintained at 100%
until the end (at 13 to 18 min). NAD+ eluted as a sharp peak at 3.3 min and was quantified on the basis of the peak area ratio between
NAD+ and the internal standard and normalized to tissue weight.
Plasma Clinical Traits of BXD Cohorts
Plasma parameters weremeasured on 2 times diluted samples (1:1 ratio of plasma to diluent) using DimensionXpand Plus (Siemens
Healthcare Diagnostics AG, Dudingen, Switzerland). The biochemical tests were performed according to the manufacturer instruc-
tions for each parameters: AST (Siemens Healthcare, DF41A), ALT (Siemens Healthcare, DF143), Glucose (Siemens Healthcare,
DF40), HDL (Siemens Healthcare, DF48B), LDL (Siemens Healthcare, DF131), Cholesterol (Siemens Healthcare, DF27), LDH
(Siemens Healthcare, DF54), TG (Siemens Healthcare, DF69A) and FFA (FUJIFILM Wako Dignostics, NEFA-HR (2)). Insulin concen-
tration was measured with an ELISA assay kit (Mouse Insulin ELISA Kit; Mercodia).
Clinical traits used for correlation of lipid signatures with metabolic phenotypes in C57BL/6J mice (Figure 6B) were obtained from
our previous study (Gariani et al., 2016). BXD metabolic and clinical data can be obtained from (Williams et al., 2016) and also avail-
able on GeneNetwork (http://www.genenetwork.org).
Lipidomics Sample Preparation and Analysis
Internal Standards (IS) Used
For BXD plasma samples we used Q6, PC(15:0/15:0), PS(17:0/17:0), PE(15:0/15:0), PA(17:0/17:0), PG(15:0/15:0), CL(56:0) and
FA(15:0/15:0) as internal standards. For NAFLD lipid signature validation experiments in mice and human samples (Figure 6), we
used the standard mix SPLASH Lipidomix Mass Spec Standard j 330707, supplemented with Q6 and CL(56:0).Cell Systems 6, 1–13.e1–e6, June 27, 2018 e4
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Lipid extraction was performed as previously described (Stefely et al., 2016). In brief, 20 ml of IS was added to 20 ml of thawed plasma
samples and vortexed (30 s). Chloroform/methanol (1:1, v/v, 1000 mL) was added and samples vortexed (60 s). Subsequently,
hydrochloric acid (1M, 200 mL) was added to induce phase separation, followed by 60 s vortex and centrifugation (3,000 g, 3 min,
4C) to complete phase separation. 550 mL of the organic phase was dried under Ar2(g). The organic residue was reconstituted in
amixture of acetonitrile (ACN)/isopropyl alcohol (IPA)/water (H2O) (65:30:5, v/v/v, 100mL) by vortexing (60 s) and transferred to a glass
vial for LC-MS analysis. Samples were stored at -80C until further use.
Discovery Lipidomics
LC-MS analysis was performed on an Ascentis Express C18 column (150 mm x 2.1 mm x 2.7 mm particle size, Waters) using an
Accela LC Pump (400 mL/min flow rate, Thermo Scientific, San Jose, CA). Mobile Phase A consisted of 10 mM ammonium acetate
in ACN/H2O (70:30, v/v) containing 250 mL/L acetic acid. Mobile phase B consisted of 10 mM ammonium acetate in IPA/ACN (90:10,
v/v) with the same additives. Mobile phase B started at 2% and increased to 85% over 20 min, then increased to 99% over 1 min and
held there for 7 min. The column was reequilibrated for 2 min before the next injection. 10 mL of sample was injected for each run. The
LC systemwas coupled to a Q Exactivemass spectrometer by a HESI II heated ESI source kept at 300C. The inlet capillary was kept
at 300C, sheath gas was set to 25 units, and auxiliary gas to 10 units. Spray voltage was set to 3,000 V and the MS was operated
in polarity switching mode. Ions from 200-1,600 m/z were isolated (Top 2) for fragmentation by stepped higher-energy collisional
dissociation (HCD) (20, 30, 40).
Lipid Species Measurement and Normalization
The resulting spectra were processed using LipidSearch (Thermo Scientific), an automated lipid identification and quantification soft-
ware inwhich acquiredMS2s are compared to a lipid database containingmore than 1.5million lipid ions and their predicted fragment
ions. Peaks were detected and lipids identified by comparing their fragmentation to predicted fragmentation pattern (m-score > 25).
Results from each sample were aligned (RT tolerance of 0.25 min, c-score >25) and quantified by integration of the MS1 peak. After
elimination of all lipidswith a gradeCor lower, the remaining lipids identity and quantificationwas verified bymanual inspection. Basic
quality check and QTL analysis was performed on all datasets normalized differently (normalized to IS, to total lipids and to the lipid
class), however, the dataset normalized to total lipids was used for all the analysis and figures shown in this paper due to overall low
relative standard deviation in this dataset (data not shown). Normalization to total lipids also has twomajor advantages over the other
normalization methods; 1) all lipids measured did not have a true internal standard, 2) for lipid classes that have few lipid species
measured, normalizing to class will be largely driven by one or two highly abundant lipids. Quality assessments of the MS measure-
ments was performed by comparing the reproducibility of the technical and extraction replicates (Figure S1). Note: lipid pairs marked
with "_1" and "_2" (TAG 54:5, 54:6 and 58:10) indicate two isobaric peaks. The two peaks are chromatographically separated and
consist of unique combinations of fatty acid tails, despite the total number of carbon molecules and double bonds being equivalent.
QUANTIFICATION AND STATISTICAL ANALYSIS
Bioinformatic and Genetic Analyses
Data normality was checked by the Shapiro-Wilk test in R, with a W R 0.90 considered normal distribution. Correlations are
Pearson’s r or Spearman’s rho as indicated in the figures. Student’s t-test was used for two groups comparisons in normal data
of equal variances, and Welch’s t-test otherwise. Heatmaps were generated using the ‘‘heatmap.2’’ function in R. PCA analysis
was performed using ‘‘prcomp’’ function in R. Unweighted correlation network graphs were performed using Spearman correlation,
keeping all edges with p-values less than 1e-05 in both CD and HFD in R using the custom package imsbInfer, currently on Github
(https://github.com/wolski/imsbInfer). GO-BP pathway enrichment analysis (Figure S5G) was performed using the R package
‘‘clusterProfiler’’ (Yu et al., 2012) (https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html). Enriched pathways
after Benjamini-Hochberg correction (p < 0.05) are shown in the figures.
Heritability (h2) was calculated by one-way (CD/HFD) or two-way (Mixed) ANOVA. The variance explained by GxE, diet and unex-
plained variance (non-dietary, non-genetic) was calculated by two-way ANOVA. QTL calculations were performed using the R/qtl
(v 1.39-5) package (Broman et al., 2003) on the log2 transformed data. The BXD genotype used for QTL calculations is provided
in the Supplemental Information (Table S8). Parametric QTL calculation was performed for normally distributed lipids and non-
parametric QTLs were determined for lipids, those were not normally distributed. QTLs with logarithm of the odds ratio (LOD)
score >2.5 and p-value <0.40 were used for all the analysis, which includes both significant (p-value < 0.05) and suggestive QTLs
(p-value between 0.05 and 0.40) at genome-wide significant threshold, computed by permutation analysis. [Genome-wide p-values
of 0.63 correspond approximately to a local p-value of 0.05, i.e. which is significant in case of prior knowledge used to search for a
QTL at that specific location].
All graphs and analyses were either made in R or GraphPad. For R, standard R plotting packages included in gplots or ggplot2—
e.g., stripchart, plotCI, and barplot2 were used. Final figures were all prepared with Adobe Illustrator.
QTL Candidate Gene Retrieval
For retrieving lQTL genes, biomaRt was used in R to obtain list of genes located within each QTL region (+/- 5Mb around themapped
SNP). Geneswith nsSNP/ncSNP/indel in BXDs (Wang et al., 2016) under each lQTLwith LOD score >2.5 and p-value <0.40were then
filtered and represented in Table S4 and use for all figures and tables reporting lQTL genes.e5 Cell Systems 6, 1–13.e1–e6, June 27, 2018
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Human GWAS genes (having p-value <1e-07) were retrieved from the database GWASdb2 (http://jjwanglab.org/gwasdb) (Li et al.,
2016) and complemented with the data from the GWAS Catalog (https://www.ebi.ac.uk/gwas/) (MacArthur et al., 2017). The cate-
gories of GWAS gene-sets retrieved from these databases included ‘‘Abnormality of lipid metabolism’’ and ‘‘fatty liver disease’’.
Additionally, published papers reporting the relevant GWAS studies, not included in the above-mentioned databases (in particular,
the references indicated by their PMID in Table S5) were manually mined to retrieve the candidate genes having p-value <1e-07.
Taken together, the compiled list comprised of 494 genes (Table S5). These GWAS genes were used for searching for their presence
under the lQTLs. Only those lQTL genes (± 5Mbon either side of the peakQTL) having non-synonymous SNPs in BXDswerematched
for any evidence of them being associated with abnormal lipid metabolism in human GWAS (i.e. matched for their presence in
494 human GWAS genes).
DATA AND SOFTWARE AVAILABILITY
Raw MS data files are available through the CHORUS project data repository (Project ID 1432, Experiment ID 3219). Additionally,
normalizedMS data is deposited in GeneNetwork (http://www.genenetwork.org) as a resource for public use. To access and analyze
the data in GeneNetwork, choose ‘‘Mouse (mm10)’’ for ‘‘Species’’, ‘‘BXD’’ for ‘‘Group’’, ‘‘Phenotypes’’ for ‘‘Type’’, ‘‘BXD Published
Phenotype’’ for ‘‘Data Set’’ and enter ‘‘PlasmaLipidomics’’ for ‘‘Get Any’’. NormalizedMS data (normalized to total lipids) is provided
in Table S1. Lipid QTLs are provided in Table S4. Lipid species andmetabolic trait correlations is provided in Table S7. BXD genotype
data used for QTL calculation is provided in Table S8.Cell Systems 6, 1–13.e1–e6, June 27, 2018 e6
